Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck Kgaa Dm 5 (MKGAF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 15,672,935
  • Shares Outstanding, K 129,240
  • Annual Sales, $ 14,254 M
  • Annual Income, $ 1,237 M
  • 36-Month Beta 0.79
  • Price/Sales 3.65
  • Price/Cash Flow N/A
  • Price/Book 1.07
  • Price/Earnings ttm 19.56
  • Earnings Per Share ttm 1.75
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/18/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.5000 +7.36%
on 04/24/17
124.4000 -2.91%
on 05/12/17
+11.0200 (+10.04%)
since 04/21/17
3-Month
105.3600 +14.64%
on 03/09/17
124.4000 -2.91%
on 05/12/17
+12.5300 (+11.58%)
since 02/22/17
52-Week
94.8700 +27.31%
on 06/27/16
124.4000 -2.91%
on 05/12/17
+22.2900 (+22.63%)
since 05/19/16

Most Recent Stories

More News
Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase

Merck KGaA (MKGAF) reported first-quarter 2017 earnings of $1.28 per American Depositary Share, 14.7% lower than the year-ago figure of $1.50.

RHHBY : 34.4300 (+0.39%)
PFE : 32.12 (-1.05%)
MKGAF : 120.7800 (-0.40%)
BMY : 54.10 (+0.15%)
Merck KGaA (MKGAF) Q1 Earnings Down Y/Y, 2017 View Updated

The company???s first-quarter 2017 earnings per American Depositary Receipt (ADR) came in at $1.28, compared to the year-ago figure of $1.50

MKGAF : 120.7800 (-0.40%)
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

AZN : 33.95 (+0.15%)
EDIT : 17.45 (-2.57%)
PFE : 32.12 (-1.05%)
MKGAF : 120.7800 (-0.40%)
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?

Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.

BMRN : 90.49 (+1.41%)
PFE : 32.12 (-1.05%)
MKGAF : 120.7800 (-0.40%)
BMY : 54.10 (+0.15%)
Is BioMarin (BMRN) Well Poised for Growth in 2017?

We issued an updated research report on BioMarin Pharmaceutical Inc. (BMRN) on Jan 25.

ENDP : 11.84 (-0.34%)
SRPT : 32.68 (-5.66%)
BMRN : 90.49 (+1.41%)
MKGAF : 120.7800 (-0.40%)
Merck KGaA, Vertex Announce Tie-Up for Oncology Programs

Merck (MKGAF) and Vertex (VRTX) collaborated for the development and commercialization of four research and development programs for the treatment of cancer.

SCMP : 10.65 (+0.95%)
VRTX : 118.94 (+0.78%)
PFE : 32.12 (-1.05%)
MKGAF : 120.7800 (-0.40%)
BioMarin (BMRN) Raised to Buy: Should You Add the Stock?

The Zacks Investment Research upgraded BioMarin (BMRN) to a Zacks #2 Rank (Buy).

BMRN : 90.49 (+1.41%)
VNDA : 14.20 (-0.35%)
MNKD : 1.37 (+21.24%)
MKGAF : 120.7800 (-0.40%)
Merck KGaA (MKGAF) Expands Distribution Deal with Roche

Merck (MKGAF) announced that it has expanded the distribution alliance with Roche (RHHBY) to include enzyme products ??? PCR and qPCR.

RHHBY : 34.4300 (+0.39%)
VNDA : 14.20 (-0.35%)
MKGAF : 120.7800 (-0.40%)
CBM : 52.25 (+0.19%)
Pfizer/Merck KGaA: Priority Review for Cancer Drug Avelumab

Pfizer, Inc. (PFE) and German partner Merck KGaA (MKGAF) announced that the Biologics License Application for avelumab, has been accepted for priority review by the FDA.

MRK : 64.04 (+0.41%)
AMGN : 153.02 (-2.23%)
PFE : 32.12 (-1.05%)
MKGAF : 120.7800 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Support & Resistance

2nd Resistance Point 120.7800
1st Resistance Point 120.7800
Last Price 120.7800
1st Support Level 120.7800
2nd Support Level 120.7800

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.